Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 48Active not recruiting 26Terminated 22Recruiting 18Withdrawn 7Unknown 7Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Lymphoma 1Histiocytic Sarcoma 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1

Interventions

Cyclophosphamide 9Vincristine 6Specimen Handling 6Prednisone 6Rituximab 5Doxorubicin 5Magnetic Resonance Spectroscopy 4zanubrutinib 3prednylidene 3fludarabine 3deltacortene 3Biopsy 3tazemetostat 2fludarabine phosphate 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1brincidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × pembrolizumab × Lymphoid × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡